Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are predicting strong results driven by the strong demand of Lilly's blockbuster drugs, particularly its insulin portfolio. However, there are also concerns about potential headwinds from regulatory scru